PD-1 blockade induces responses by inhibiting adaptive immune resistance

Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clinical responses in patients with various cancer types.(1–5) One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Tumeh, Paul C., Harview, Christina L., Yearley, Jennifer H., Shintaku, I. Peter, Taylor, Emma J. M., Robert, Lidia, Chmielowski, Bartosz, Spasic, Marko, Henry, Gina, Ciobanu, Voicu, West, Alisha N., Carmona, Manuel, Kivork, Christine, Seja, Elizabeth, Cherry, Grace, Gutierrez, Antonio, Grogan, Tristan R., Mateus, Christine, Tomasic, Gorana, Glaspy, John A., Emerson, Ryan O., Robins, Harlan, Pierce, Robert H., Elashoff, David A., Robert, Caroline, Ribas, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418/
https://www.ncbi.nlm.nih.gov/pubmed/25428505
http://dx.doi.org/10.1038/nature13954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418/
https://www.ncbi.nlm.nih.gov/pubmed/25428505
http://dx.doi.org/10.1038/nature13954

Ejemplares similares